Vaxcyte
Preço: 47.46Empresa e modelo de negócios
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to address infectious diseases. Its core products include a pipeline of vaccine candidates targeting various pathogens, with a primary emphasis on pneumococcal disease. The company operates within the healthcare sector, primarily generating revenue through research and development activities and potential future product sales.
Perfil de investimento
The investment profile of Vaxcyte is more aligned with growth investors, given its focus on developing new vaccine technologies and the potential for significant future revenue from successful product launches. The stock may appeal to those with a medium to long-term investment horizon, as the company is still in the development phase. Liquidity is moderate, suitable for investors with basic to advanced experience in the biotech sector.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -6.89 Risco
- Surpresa de EPS
- -29.7% pior que o esperado
- Volatilidade 20d
- 3.1% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-03 02:49 | Manter | Vender | scenario_deterioration |
| 2026-05-28 02:54 | Vender | Manter | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-20 02:53 | Manter | Vender | scenario_deterioration |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-02-25 19:27 | BTIG | Preço-alvo elevado | — → 89 | 63.04 |
| 2025-11-19 10:23 | Leerink Partners | Preço-alvo elevado | — → 77 | 49.53 |
Nada ainda